Sa A. Wang

15.6k total citations
280 papers, 5.4k citations indexed

About

Sa A. Wang is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Sa A. Wang has authored 280 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 181 papers in Hematology, 124 papers in Genetics and 84 papers in Pathology and Forensic Medicine. Recurrent topics in Sa A. Wang's work include Acute Myeloid Leukemia Research (149 papers), Lymphoma Diagnosis and Treatment (80 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (66 papers). Sa A. Wang is often cited by papers focused on Acute Myeloid Leukemia Research (149 papers), Lymphoma Diagnosis and Treatment (80 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (66 papers). Sa A. Wang collaborates with scholars based in United States, China and Switzerland. Sa A. Wang's co-authors include L. Jeffrey Medeiros, Guilin Tang, Jeffrey L. Jorgensen, Robert P. Hasserjian, Hagop M. Kantarjian, Roberto N. Miranda, Carlos E. Bueso‐Ramos, Farhad Ravandi, Joseph D. Khoury and Guillermo Garcia‐Manero and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Sa A. Wang

267 papers receiving 5.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sa A. Wang United States 38 3.2k 1.8k 1.2k 1.2k 1.1k 280 5.4k
Guido Kobbe Germany 40 3.8k 1.2× 1.3k 0.7× 610 0.5× 1.3k 1.1× 1.0k 0.9× 204 5.2k
Yang O. Huh United States 35 2.4k 0.8× 1.6k 0.9× 1.3k 1.0× 1.2k 0.9× 1.2k 1.0× 104 4.7k
David S. Viswanatha United States 32 1.2k 0.4× 966 0.5× 1.8k 1.4× 1.1k 0.9× 813 0.7× 133 3.6k
Anthony S. Stein United States 43 3.9k 1.2× 934 0.5× 873 0.7× 2.9k 2.3× 1.8k 1.6× 242 6.8k
Auayporn Nademanee United States 39 3.1k 1.0× 1.3k 0.7× 3.2k 2.6× 3.3k 2.7× 823 0.7× 180 7.3k
Preetesh Jain United States 32 1.4k 0.5× 2.2k 1.2× 1.5k 1.2× 1.0k 0.8× 267 0.2× 181 3.7k
Haifa Kathrin Al‐Ali Germany 30 3.2k 1.0× 3.2k 1.8× 752 0.6× 822 0.7× 395 0.3× 166 4.9k
Ivana N. Micallef United States 45 2.9k 0.9× 1.7k 1.0× 3.3k 2.7× 3.2k 2.6× 456 0.4× 256 7.4k
Corrado Tarella Italy 41 2.5k 0.8× 1.5k 0.8× 2.8k 2.2× 2.8k 2.3× 373 0.3× 213 6.2k
Ulrike Bacher Germany 39 4.1k 1.3× 2.1k 1.1× 622 0.5× 1.1k 0.9× 801 0.7× 281 5.7k

Countries citing papers authored by Sa A. Wang

Since Specialization
Citations

This map shows the geographic impact of Sa A. Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sa A. Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sa A. Wang more than expected).

Fields of papers citing papers by Sa A. Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sa A. Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sa A. Wang. The network helps show where Sa A. Wang may publish in the future.

Co-authorship network of co-authors of Sa A. Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Sa A. Wang. A scholar is included among the top collaborators of Sa A. Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sa A. Wang. Sa A. Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wang, Sa A., et al.. (2024). Precision engineering of antibodies: A review of modification and design in the Fab region. International Journal of Biological Macromolecules. 275(Pt 2). 133730–133730. 4 indexed citations
3.
Kantarjian, Hagop M., David McCue, Fadi Haddad, et al.. (2024). Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia. Leukemia & lymphoma. 65(9). 1325–1334. 4 indexed citations
4.
Fang, Hong, Sa A. Wang, Hannah C. Beird, et al.. (2024). Morphology, immunophenotype, and suggested diagnostic criteria of TCL1 family–negative T-prolymphocytic leukemia. American Journal of Clinical Pathology. 162(6). 582–590. 1 indexed citations
5.
Loghavi, Sanam, Qing Wei, Farhad Ravandi, et al.. (2024). Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia. American Journal of Hematology. 99(10). 1959–1968. 17 indexed citations
6.
Liu, Yen‐Chun, Sa A. Wang, Jacob R. Bledsoe, et al.. (2024). Clinical, immunophenotypic, and genomic findings of acute myeloid leukemia with RAM immunophenotype: Comparison with other CD56‐positive acute leukemias. SHILAP Revista de lepidopterología. 6(1). e1052–e1052. 2 indexed citations
7.
Sasaki, Koji, Sanam Loghavi, Sa A. Wang, et al.. (2024). Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression. British Journal of Haematology. 204(6). 2259–2263. 3 indexed citations
8.
Wang, Sa A., Jeffrey L. Jorgensen, Shimin Hu, et al.. (2023). Validation of a 12‐color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection. Cytometry Part B Clinical Cytometry. 104(5). 356–366. 10 indexed citations
9.
Chen, Weina, Adam Bagg, Prasad Koduru, et al.. (2023). Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group. Leukemia Research. 130. 107309–107309. 4 indexed citations
10.
Thompson, Philip A., Michael J. Keating, Alessandra Ferrajoli, et al.. (2023). Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD. Leukemia. 37(7). 1444–1453. 2 indexed citations
11.
Jabbour, Elias, Fadi Haddad, Nicholas J. Short, et al.. (2023). Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 143(5). 417–421. 25 indexed citations
12.
Wang, Sa A., et al.. (2023). Beyond traditional light: NIR-II light-activated photosensitizers for cancer therapy. Journal of Materials Chemistry B. 11(35). 8315–8326. 39 indexed citations
13.
Qiu, Lianqun, L. Jeffrey Medeiros, Guilin Tang, et al.. (2021). The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, TP53 Deletion, and a Poor Prognosis. Cancers. 13(24). 6316–6316. 5 indexed citations
14.
Rogers, Heesun J., Xiaoqiong Wang, Yan Xie, et al.. (2020). Comparison of therapy‐related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. American Journal of Hematology. 95(7). 799–808. 22 indexed citations
15.
Quesada, Andres, Mark J. Routbort, Courtney D. DiNardo, et al.. (2019). DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high‐risk disease. American Journal of Hematology. 94(7). 757–766. 71 indexed citations
16.
17.
Goyal, Tanu, Beenu Thakral, Sa A. Wang, et al.. (2017). T-Cell Large Granular Lymphocytic Leukemia and Coexisting B-Cell Lymphomas. American Journal of Clinical Pathology. 149(2). 164–171. 13 indexed citations
18.
19.
Shen, Qi, Juan Ouyang, Guilin Tang, et al.. (2014). Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. European Journal Of Haematology. 95(2). 168–176. 24 indexed citations
20.
Ciurea, Stefan O., Peter F. Thall, Xuemei Wang, et al.. (2011). Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood. 118(22). 5957–5964. 148 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guido Kobbe Breakdown of academic impact, for papers by Yang O. Huh Breakdown of academic impact, for papers by David S. Viswanatha Breakdown of academic impact, for papers by Anthony S. Stein Breakdown of academic impact, for papers by Auayporn Nademanee Breakdown of academic impact, for papers by Preetesh Jain Breakdown of academic impact, for papers by Haifa Kathrin Al‐Ali Breakdown of academic impact, for papers by Ivana N. Micallef Breakdown of academic impact, for papers by Corrado Tarella Breakdown of academic impact, for papers by Ulrike Bacher
Rankless by CCL
2026